Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Clinical Trial Details
Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma
Complete Title: Olaparib in Prostate Cancer Patients With Evidence of Homologous Recombination Deficiency As Assessed Using an Integrated Genomic Signature
Trial Phase: II
Investigator: Michael Schweizer
This phase II trial investigates the effect of olaparib in treating patients with castration resistant prostate adenocarcinoma. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Keywords:
- Prostate Cancer
- Prostate Cancer, Castration-resistant (CRPC)
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact Us
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.
Adult
II
Michael Schweizer
RG1121519
NCT04951492
Olaparib in Prostate Cancer Patients With Evidence of Homologous Recombination Deficiency As Assessed Using an Integrated Genomic Signature
Prostate Cancer
Prostate Cancer, Castration-resistant (CRPC)